
|Articles|February 1, 2005
Iris pigmentation changes monitored with glaucoma therapy
Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
3
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
4
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
5















































.png)


